ArticleUrolithiasis2025
Insight into obesity associated hyperoxaluria: identifying the shared biomarkers and pathways in kidney stones and obesity by integrative bioinformatic and in vivo studies.
Article in Urolithiasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Obesity is a primary risk factor associated with kidney stones (KS), with evidence suggesting that increasing BMI, obesity, and metabolic syndrome over the past three decades correlate with an elevated risk of hyperoxaluria. However, the pathogenic mechanisms associated between obesity and kidney stones at the transcriptional level remain poorly understood. Thus, we aim to explore the hub genes related to obesity-associated hyperoxaluria (OAH) to improve the understanding of its underlying pathophysiology. To understand the gap in the underlying mechanism, we performed a comprehensive weighted gene co-expression network analysis (WGCNA) on two microarray datasets. Further, differently expressed genes (DEGs) of the kidney tissue dataset and significant key modules identified through WGCNA were analyzed to pinpoint shared biomarkers and biological pathways implicated in OAH. Subsequently, hub genes were identified by constructing Protein-protein interaction (PPI) networks. Furthermore, an in vivo animal model mimicking OAH was employed to validate the hub genes through quantitative PCR (qPCR) and histopathological evaluations. Four key modules associated with KS and obesity were identified using WGCNA. The DEGs analysis revealed 346 upregulated and 19 downregulated genes. Functional enrichment via Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, combined with PPI network insights, highlighted seven potential genes shared between KS and obesity. Further, in vivo studies demonstrated gut inflammation and kidney stone formation, as confirmed by histopathological evidence. The validation through qPCR has identified five hub genes-IL-6, TLR-4, CD44, SPP-1, and CCL-2-as key contributors to OAH pathophysiology. These findings, which provide new insights into the molecular mechanisms driving OAH, underscore the need for further studies with larger sample sizes to corroborate these findings and expand on their implications.
Indexed as
Identifiers
40214693What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.